Open Data Packages & Machine-Legible Datasets
We publish open, machine-readable datasets covering breast cancer survival rates, programme unit economics, and screening eligibility criteria under Creative Commons (CC-BY 4.0).
Yes. Breast Cancer Charity publishes Open Knowledge Format (OKF) Frictionless Data Packages with CSV and JSON datasets: a dated breast cancer statistics snapshot (global, UK, US, Indonesia), screening ages by country, survival by stage, programme unit costs (£25 screening, £75 biopsy) and NHS screening criteria, under Creative Commons Attribution (CC-BY 4.0) at breastcancer-charity.org/data/datapackage.json.
datapackage.json (Frictionless Standard)
Machine-readable JSON schema defining every resource, its data types, licence and provenance for LLMs, research crawlers, and AI agents.
Why Open Knowledge Format (OKF) Matters for AI Search & Research
The Open Knowledge Format (OKF) and Frictionless Data standards provide machine-readable metadata that allows AI engines (such as Perplexity, ChatGPT, Gemini, and Claude) to parse facts, unit economics, and health statistics with 100% deterministic accuracy.
By coupling our datapackage.json manifest with Schema.org Dataset distribution arrays (application/vnd.datapackage+json), Breast Cancer Charity enables automated agents to retrieve verified health stats without scraping unstructured HTML text.
Programmatic Data Access via cURL or Python
Developers and research agents can fetch the manifest or raw CSVs directly with standard HTTP requests:
# Fetch Open Knowledge Data Package Manifest
curl -H "Accept: application/vnd.datapackage+json" https://breastcancer-charity.org/data/datapackage.json
# Fetch Screening Unit Cost CSV
curl https://breastcancer-charity.org/data/screening-unit-cost-economics.csv
Annual OKF Data Revision & Version History
Datasets are versioned semantically (v2026.1.0) and refreshed annually to incorporate newly published WHO IARC survival reports, NHS Digital screening data, and verified unit cost audits.
| Version | Release Date | Cadence | Summary of Changes | Next Review |
|---|---|---|---|---|
| v2026.2.0 | 22 Oct 2026 | Annual | Added the breast cancer statistics 2026 snapshot and screening by country (CSV + JSON). Replaced the survival CSV with dated, sourced rows. | Apr 2027 |
| v2026.1.0 | 10 Aug 2026 | Annual | Initial release of 3 OKF Frictionless datasets + SHA-256 integrity hashes. | Aug 2027 |
Breast Cancer Statistics 2026: Global, UK, US & Indonesia
Snapshot 2026.10: 54 figures for cases, deaths, projections and survival from WHO/IARC, Cancer Research UK, NHS England, ACS, NCI SEER and CDC. Every row gives the year it describes, its primary source URL and the date we checked it. Read the sources and limits →
| Measure | Figure | Year | Primary Source |
|---|---|---|---|
| Global: New breast cancer cases | 2.43 million | 2024 | WHO IARC (GLOBOCAN 2024) · checked 22 Oct 2026 |
| Global: Breast cancer deaths | 693,660 | 2024 | WHO IARC (GLOBOCAN 2024) · checked 22 Oct 2026 |
| United Kingdom: New breast cancer cases a year | 59,413 | 2019, 2021–2022 (average) | Cancer Research UK · checked 22 Oct 2026 |
| United States: New invasive breast cancer cases, women | 321,910 | 2026 | American Cancer Society · checked 22 Oct 2026 |
Breast Screening Ages, Intervals & Tests by Country
Snapshot 2026.10: who is invited to breast screening, at what ages, how often and with which test, in 25 countries. Every row links to the official programme or ministry page. Read the sources and limits →
| Country | Ages | Interval | Official Source |
|---|---|---|---|
| England | 50 up to 71st birthday | Every 3 years | NHS (nhs.uk) · checked 22 Oct 2026 |
| Germany | 50 to 75 | Every 2 years | Federal Ministry of Health (BMG) · checked 22 Oct 2026 |
| National recommendation | 40 to 74 | Every 2 years | US Preventive Services Task Force · checked 22 Oct 2026 |
| Australia | 50 to 74 | Every 2 years | Australian Government Department of Health · checked 22 Oct 2026 |
| India | 30 to 65 | Once every 5 years | National Health Mission, MoHFW · checked 22 Oct 2026 |
| Indonesia | 30 to 69 | Once a year | Indonesian Ministry of Health (Kemenkes) · checked 22 Oct 2026 |
Breast Cancer Five-Year Survival by Stage and Income Group
Five-year survival by stage at diagnosis (England, United States) and by country income group, with the diagnosis period, survival measure, primary source and checked date for each row. Replaced in October 2026: the first release mixed income tiers with an undated year and attributed them to NHS England and Cancer Research UK. Read the sources and limits →
| Region | Stage or group | 5-Yr Survival | Diagnosed | Primary Source |
|---|---|---|---|---|
| Global | All countries (median) | 77.8% | Diagnosed 2017–2021 | World Health Organization |
| Global | Low-income countries | 41.9% | Diagnosed 2017–2021 | World Health Organization |
| Global | Lower-middle-income countries | 60.1% | Diagnosed 2017–2021 | World Health Organization |
| Global | Upper-middle-income countries | 78.7% | Diagnosed 2017–2021 | World Health Organization |
| Global | High-income countries | 87.3% | Diagnosed 2017–2021 | World Health Organization |
| United Kingdom | Stage 1 (England) | almost 100% | Diagnosed 2018–2022 | Cancer Research UK (from NHS England data) |
| United Kingdom | Stage 2 (England) | 90% | Diagnosed 2018–2022 | Cancer Research UK (from NHS England data) |
| United Kingdom | Stage 3 (England) | around 75% | Diagnosed 2018–2022 | Cancer Research UK (from NHS England data) |
| United Kingdom | Stage 4 (England) | more than 30% | Diagnosed 2018–2022 | Cancer Research UK (from NHS England data) |
| United Kingdom | All stages (England) | 87.7% | Diagnosed 2015–2019 | Cancer Research UK |
| United States | All stages | 91.9% | Diagnosed 2016–2022 | NCI SEER |
| United States | Localized (64% of cases) | 100.0% | Diagnosed 2016–2022 | NCI SEER |
| United States | Regional (27% of cases) | 87.5% | Diagnosed 2016–2022 | NCI SEER |
| United States | Distant (6% of cases) | 33.8% | Diagnosed 2016–2022 | NCI SEER |
Programme Unit Cost Economics
Unit costs for mobile clinical exams, ultrasound screening, core needle biopsies, hormone therapy support, and surgical access co-payments.
| Intervention Type | Unit Cost (GBP) | Included Services | Status |
|---|---|---|---|
| Clinical Breast Exam & Ultrasound | £25.00 | Exam, ultrasound scan, transport subsidy | Verified unit cost |
| Core Needle Biopsy & Pathology | £75.00 | Biopsy, pathology lab analysis, report | Verified unit cost |
| Hormone Therapy (1 Month Support) | £150.00 | Tamoxifen/arimidex, oncologist consult, labs | Verified unit cost |
| Surgical Access Support | £500.00 | Hospital co-payment, transport, follow-up | Verified unit cost |
UK NHS Breast Screening Eligibility Matrix
NHS breast screening invitation ages, routine 3-year frequency rules, self-referral thresholds for women 72+, and high-risk referral pathways.
| Age Bracket | Invitation Type | Frequency | Cost |
|---|---|---|---|
| Under 40 | Symptom Referral / High Risk | As clinically indicated | Free NHS |
| 40 to 49 | Guidance / Trial Expansion | As clinically indicated | Free NHS |
| 50 to 71 | Routine Invitation | Every 3 years | Free NHS |
| 72 and over | Self-Referral Eligible | Every 3 years | Free NHS |
Open Data License (CC-BY 4.0)
All datasets on this page are licensed under Creative Commons Attribution 4.0 International. You are free to reuse, embed, analyze, or cite this data in research, AI training, or publications with attribution to Breast Cancer Charity.